Quick Answer
ZEVRA THERAPEUTICS, INC. reported Cash and Equivalents of $62.41 million for fiscal year 2025.
ZEVRA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $62.41M | +84.7% |
| 2024 | $33.78M | -21.5% |
| 2023 | $43.05M | -34.2% |
| 2022 | $65.47M | -41.7% |
| 2021 | $112.35M | +2566.7% |
| 2020 | $4.21M | +31.0% |
| 2019 | $3.22M | -82.5% |
| 2018 | $18.41M | +69.3% |
| 2017 | $10.87M | -35.1% |
| 2016 | $16.76M | -48.1% |
| 2015 | $32.32M | +215.1% |
| 2014 | $10.26M | +420.8% |
| 2013 | $1.97M | -22.5% |
| 2012 | $2.54M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.44M | +0.7% | +14.1% |
| June 30, 2025 | $47.71M | +21.5% | +27.8% |
| March 31, 2025 | $37.34M | -12.9% | +10.5% |
| December 31, 2024 | $33.78M | -21.5% | -37.5% |
| September 30, 2024 | $54.04M | +24.9% | +37.6% |
| June 30, 2024 | $39.26M | -40.7% | -8.4% |
| March 31, 2024 | $42.85M | +6.6% | -0.5% |
| December 31, 2023 | $43.05M | -34.2% | -0.5% |
- ZEVRA THERAPEUTICS, INC. showed an increase of +84.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, ZEVRA THERAPEUTICS, INC.’s cash and equivalents has grown by 2355.0% (from $2.54 million to $62.41 million).
- The most recent figure is from ZEVRA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: